Jefferies Financial Group Brokers Decrease Earnings Estimates for Establishment Labs Holdings Inc (ESTA)

Share on StockTwits

Establishment Labs Holdings Inc (NASDAQ:ESTA) – Equities research analysts at Jefferies Financial Group dropped their Q2 2019 earnings per share (EPS) estimates for Establishment Labs in a research note issued on Wednesday, May 15th. Jefferies Financial Group analyst R. Denhoy now expects that the company will earn ($0.52) per share for the quarter, down from their previous estimate of ($0.51). Jefferies Financial Group also issued estimates for Establishment Labs’ Q3 2019 earnings at ($0.51) EPS, Q4 2019 earnings at ($0.37) EPS, FY2019 earnings at ($1.92) EPS, FY2020 earnings at ($1.47) EPS, FY2021 earnings at ($1.31) EPS, FY2022 earnings at ($0.86) EPS and FY2023 earnings at $0.26 EPS.

Separately, BTIG Research reiterated a “buy” rating and issued a $40.00 target price on shares of Establishment Labs in a report on Monday, March 25th.

Shares of ESTA stock opened at $26.25 on Monday. Establishment Labs has a twelve month low of $20.05 and a twelve month high of $30.70. The firm has a market capitalization of $532.47 million and a price-to-earnings ratio of -23.44. The company has a debt-to-equity ratio of 0.38, a current ratio of 5.54 and a quick ratio of 4.54.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Wednesday, May 15th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.13). Establishment Labs had a negative return on equity of 68.22% and a negative net margin of 37.74%. The firm had revenue of $20.78 million during the quarter, compared to analysts’ expectations of $18.50 million.

Hedge funds have recently modified their holdings of the business. Morgan Stanley lifted its holdings in shares of Establishment Labs by 43.5% in the 1st quarter. Morgan Stanley now owns 3,584 shares of the company’s stock worth $86,000 after buying an additional 1,087 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Establishment Labs by 226.8% in the 1st quarter. JPMorgan Chase & Co. now owns 6,628 shares of the company’s stock worth $159,000 after buying an additional 4,600 shares during the period. Northern Trust Corp lifted its holdings in shares of Establishment Labs by 187.3% in the 1st quarter. Northern Trust Corp now owns 25,296 shares of the company’s stock worth $608,000 after buying an additional 16,491 shares during the period. Opaleye Management Inc. purchased a new stake in shares of Establishment Labs in the 1st quarter worth $1,202,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Establishment Labs by 159.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 102,900 shares of the company’s stock worth $2,822,000 after buying an additional 63,300 shares during the period. Institutional investors and hedge funds own 23.14% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.

Featured Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Amcor plc  Given $10.74 Average Target Price by Brokerages
Amcor plc Given $10.74 Average Target Price by Brokerages
Zacks: EP Energy Corporation  Given $1.21 Consensus Target Price by Analysts
Zacks: EP Energy Corporation Given $1.21 Consensus Target Price by Analysts
Brokerages Expect Stoke Therapeutics  to Post  Earnings Per Share
Brokerages Expect Stoke Therapeutics to Post Earnings Per Share
Zacks: Analysts Expect CNH Industrial NV  to Post $0.29 Earnings Per Share
Zacks: Analysts Expect CNH Industrial NV to Post $0.29 Earnings Per Share
Exelixis, Inc.  Expected to Announce Earnings of $0.25 Per Share
Exelixis, Inc. Expected to Announce Earnings of $0.25 Per Share
Zacks: Analysts Anticipate Triplepoint Venture Growth BDC Corp  to Announce $0.38 Earnings Per Share
Zacks: Analysts Anticipate Triplepoint Venture Growth BDC Corp to Announce $0.38 Earnings Per Share


© 2006-2019 Ticker Report